Gracell Biotechnologies Stock Price, News & Analysis

GRCL NASDAQ

Company Description

Gracell Biotechnologies (NASDAQ: GRCL) is a publicly traded pharmaceutical preparation manufacturing company in the Manufacturing sector.

GRCL stock has declined 100.0% over the past year.

This page provides a comprehensive overview of GRCL stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$0.0

Market Cap

96.6M

Shares outstanding

Gracell Biotechnologies (GRCL) stock. Over the past 12 months, the stock has lost 100.0%.

Latest News

View All

February 22, 2024

0.00%

Gracell Biotechnologies Acquisition Completed

acquisition

February 20, 2024

+1.04%

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

acquisition

January 29, 2024

+1.19%

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

clinical trial fda approval

December 26, 2023

+60.26%

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

acquisition

December 26, 2023

+60.26%

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

acquisition

December 21, 2023

+5.79%

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

clinical trial

Gracell Biotechnologies has 10 recent news articles. Of the recent coverage, 9 articles coincided with positive price movement and 0 with negative movement. Key topics include acquisition, clinical trial, fda approval, conferences, earnings. View all GRCL news →

SEC Filings

View All

No SEC filings available for GRCL.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

GRCL Company Profile & Sector Positioning

Gracell Biotechnologies (GRCL) operates in the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.